CClinicalTrials.gg
Sign In
CompletedNCT05444049ARISEUpdated Oct 9, 2025

NEURESCUE Device as an Adjunct to In-Hospital Cardiac Arrest (ARISE)

An interventional study of NEURESCUE device in Cardiac Arrest, Cardiopulmonary Arrest and Cardiovascular Diseases, sponsored by neurescue. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by neurescue · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The NEURESCUE device is the first intelligent catheter for aortic balloon occlusion, an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment.

The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.

The objective of this study is to investigate the feasibility of the NEURESCUE device as an adjunct to Advanced Cardiac Life Support (ACLS) in adults with cardiac arrest.

02

Conditions studied

  • Cardiac Arrest
  • Cardiopulmonary Arrest
  • Cardiovascular Diseases
03

In context

Heart Arrest

966 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

This study's enrollment of 6 is below the median of 100 across 557 interventional studies indexed under Heart Arrest.

Browse Heart Arrest studies →

Lead sponsor

neurescue is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age ≥18 and ≤80 years
  2. CPR initiated within 7 min of presumed arrest
  3. 8 min of continuous ACLS without ROSC

Exclusion criteria

Exclusion Criteria:

  1. Traumatic cardiac arrest
  2. Intraoperative cardiac arrest
  3. Known pregnancy
  4. Known terminal disease
  5. Known do-not-attempt-CPR order
  6. Subjects whose femoral arterial access site cannot accommodate an 8 Fr introducer sheath
  7. Subjects currently on mechanical circulatory support
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Treatment

    The NEURESCUE device will be used as an adjunct to ACLS.

    Device: NEURESCUE device

Interventions

  • DeviceNEURESCUE device

    The balloon catheter is delivered via the femoral artery, temporarily inflating a soft balloon in the descending aorta to redirect blood flow towards the upper body.

06

What researchers measure

Primary outcomes

  1. Successful balloon inflation within 10 minutes from first vessel puncture

    Time frame: Assessed up to 10 min

Secondary outcomes

  1. Change in central blood pressure

    Time frame: Assessed up to 1 hour

  2. Total ACLS time at initiation of the investigational procedure

    Time frame: Assessed up to 1 hour

  3. Time from first vessel puncture to successful sheath insertion

    Time frame: Assessed up to 1 hour

  4. Rate of occlusion success

    Time frame: Assessed up to 1 hour

  5. Return of spontaneous circulation (ROSC)

    The endpoint is dichotomous (yes/no) for each subject

    Time frame: Assessed up to 1 hour

07

Study locations

1 site
  • Long Beach Medical Center
    Long Beach, California 90806, United States
08

References and documents

Publications

  • Rusnak J, Thevathasan T, Skurk C, Zelniker TA, Frost H, Eden M, Speer C, Frey N, Preusch MR. Feasibility of computer-aided aortic occlusion catheter in non-traumatic cardiac arrest. Resuscitation. 2025 Dec;217:110879. doi: 10.1016/j.resuscitation.2025.110879. Epub 2025 Nov 12. PubMed 41237845 ↗

Individual participant data

Plan to share: No — Individual request

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05444049
Lead sponsor
neurescue
Responsible party
Sponsor
First posted
Jul 5, 2022
Start date
Dec 8, 2022
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Oct 9, 2025

Study contacts

David Shavelle, M.D.
principal investigator · Long Beach Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Heart Arrest→

Other studies from this sponsor

neurescue

Start the discussion